ProCE Banner Activity

Overview of CAR T-Cell Therapy in Multiple Myeloma

Slideset

Get up to date on approved and emerging CAR T-cell therapies for patients with multiple myeloma with these downloadable slides from an expert webinar.

Released: February 22, 2023

Expiration: February 21, 2024

Begin Activity

Share

Faculty

Amrita Krishnan

Amrita Krishnan, MD, FACP

Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
City of Hope
Duarte, California

Nikhil Munshi

Nikhil Munshi, MD

Professor of Medicine
Harvard Medical School
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Faculty Disclosure

Primary Author

Amrita Krishnan, MD, FACP

Director, Judy and Bernard Briskin Center for Multiple Myeloma Research
City of Hope
Duarte, California

Amrita Krishnan, MD, FACP: consultant/advisor/speaker: Adaptive, Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Pfizer, Regeneron, Sanofi, Sutro.

Nikhil Munshi, MD

Professor of Medicine
Harvard Medical School
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nikhil Munshi, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, DCT, GlaxoSmithKline, Janssen, Legend Biotech, Novartis, Oncopep, Pfizer, Takeda; other (founder and/or stock options): DCT, Oncopep.